n-heptyl mesylate | 86602-40-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 英文名称: n-heptyl mesylate
• 英文别名: 1-Methylsulfonylheptane
• CAS: 86602-40-6
• 化学式: C₈H₁₈O₂S
• 分子量: 178.296
• InChiKey: PFJDVQSHGLRPFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [14C]potassium cyanide 、 n-heptyl mesylate 生成
  参考文献：
  名称：

  Biosynthesis of elaiomycin. 1. Incorporation of labeled forms of n-octylamine

  摘要：

  DOI：

  10.1021/ja00365a084
• 作为产物：
  描述：

  N-庚基甲基硫醚 在 Ce(IV)EPBPSS₃ sodium bromate 作用下， 以 水 、 乙腈 为溶剂， 反应 0.25h， 生成 n-heptyl methyl sulphoxide 、 n-heptyl mesylate
  参考文献：
  名称：

  Selective oxidations of sulfides to sulfoxides using immobilised cerium alkyl phosphonate

  摘要：

  A range of sulfides can be selectively oxidised to the corresponding sulfoxides in good yields using catalytic quantities of immobilised cerium alkyl phosphonate and either sodium brornate or tert-butyl hydroperoxide as oxidants. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2005.04.079

文献信息

• Selective preventives/remedies for progressive lesions after organ damage
  申请人：——

  公开号：US20030181506A1

  公开（公告）日：2003-09-25

  An object of the present invention is to provide a pharmaceutical agents for preventing and/or treating the progressive lesion after the organic damage without inhibiting organic function or regeneration function thereof, by selectively suppressing the induction of cytotoxic effector macrophages which are induced into the damaged organs in response to chemokines and cytokines which are expressed depending on the type of damaged organic tissues.

  本发明的目的是提供一种药物制剂，用于在有机损伤后预防和/或治疗渐进性病变，而不抑制有机功能或再生功能，通过选择性抑制细胞毒性效应巨噬细胞的诱导，这些巨噬细胞是在损伤的器官中受化学因子和细胞因子诱导而表达的，这些化学因子和细胞因子取决于损伤的有机组织的类型。
• [EN] FUNGICIDES TO PREVENT AND CONTROL FUNGAL PATHOGENS<br/>[FR] FONGICIDES POUR LA PRÉVENTION ET LA LUTTE CONTRE DES PATHOGÈNES FONGIQUES
  申请人：UNIV LAUSANNE

  公开号：WO2020011750A1

  公开（公告）日：2020-01-16

  The invention relates to the field of biological fungicides with a broad range of antifungal activity coming from plant extracts from the order of Brassicales or molecules revealing similar chemical structure. In particular, Applicants surprisingly provided a new usage of a combination of sulfonyl and sulfinyl containing aliphatic glucosinolates, their by-products and synthetic analogues as efficient antifungal compounds with broad spectrum of activity.

  本发明涉及一种生物杀菌剂领域，其具有来自十字花目植物提取物或具有类似化学结构的分子的广谱抗真菌活性。特别地，申请人惊奇地提供了一种新的用途，即使用含有磺酰基和亚磺酰基的脂肪族葡萄糖苷、其副产物和合成类似物的组合作为具有广谱活性的高效抗真菌化合物。
• Sulfonyl Containing Compounds as Cysteine Protease Inhibitors
  申请人：Mossman Craig J.

  公开号：US20080287446A1

  公开（公告）日：2008-11-20

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及抑制半胱氨酸蛋白酶的化合物，特别是猫蛋白酶B、K、L、F和S，因此在治疗由这些蛋白酶介导的疾病方面非常有用。本发明涉及包含这些化合物的制药组合物和制备它们的方法。
• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：Asana Biosciences, LLC

  公开号：US20150125474A1

  公开（公告）日：2015-05-07

  A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.

  本文描述了一种聚合物支架，可用于与基于蛋白质的识别分子(PBRM)共轭，形成PBRM-聚合物-药物共轭物。该支架包括一个或多个末端马来酰亚胺基团。还公开了从该支架制备的PBRM-聚合物-药物共轭物。本文还描述了包含该共轭物的组合物，其制备方法以及使用该共轭物或其组合物治疗各种疾病的方法。
• SELECTIVE PREVENTIVES/REMEDIES FOR PROGRESSIVE LESIONS AFTER ORGAN DAMAGE
  申请人：Ishibashi, Michio

  公开号：EP1277747A1

  公开（公告）日：2003-01-22

  An object of the present invention is to provide a pharmaceutical agents for preventing and/or treating the progressive lesion after the organic damage without inhibiting organic function or regeneration function thereof, by selectively suppressing the induction of cytotoxic effector macrophages which are induced into the damaged organs in response to chemokines and cytokines which are expressed depending on the type of damaged organic tissues.

  本发明的目的是提供一种药剂，通过选择性地抑制细胞毒性效应巨噬细胞的诱导，预防和/或治疗机体损伤后的进行性病变，而不抑制机体功能或其再生功能。